Community Health Network Foundation names new CEO
Michele Thomas Dole has been a wealth adviser at JP Morgan Chase and development director of the IU Foundation.
Michele Thomas Dole has been a wealth adviser at JP Morgan Chase and development director of the IU Foundation.
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
Duke University researchers found a link between how a key stock index performed and how many heart attacks were treated at
their North Carolina hospital.
Indiana’s plan to lay off some meat inspectors has small, independent processors fearing for the future of what has been a
growing industry.
The Indiana Network for Patient Care announced Tuesday that Good Samaritan Hospital in Vincennes, Ind., has joined 40 other
hospitals and clinics that are part of an online network that handles one of the nation's highest volume of health information
exchanges.
Indianapolis-based PolicyStat LLC raised $1.15 million in angel capital from 31 individuals and Halo Capital Group.
The plan approved by the Republican-controlled Senate would transfer the duties of the Tobacco Use Prevention and Cessation
board to the State Department of Health.
The Indianapolis Medical Society hopes an online database that compares one doctor's reimbursement rates against market
averages helps its members negotiate with health plans.
By pounding health insurers such as WellPoint Inc., President Obama has greatly boosted his chances of success in the eyes
of Wall Street. But to make his health reform bill reality, he might need to answer the less-than-reassuring news coming from
Massachusetts.
WellPoint Inc.’s Anthem Blue Cross & Blue Shield of Connecticut may constrain competition through contracts that require
that the insurer receives hospital discounts at least as favorable as any provided to a competitor.
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Health and Human Services Secretary Kathleen Sebelius met at the White House with the CEOs of Indianapolis-based WellPoint,
Aetna, Cigna, UnitedHealth Group, as well as several state insurance commissioners.
Agricultural biotech firm hired a site-selection consultant and considered other cities around the world for its $340 million
expansion.
The investment will greatly expand the company’s research and development capacity and is a major win for the Indiana
life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
Dr. Gregory N. Larkin, the former global medical director at Eli Lilly and Co., will replace Dr. Judy Monroe, who is leaving
to become deputy director of the Centers for Disease Control and Prevention.
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Local Dow Chemical subsidiary expects to launch five new biotech products by 2012.
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
Dr. Patrick J. Loehrer Sr. replaces Dr. Stephen D. Williams, the center’s founding director, who died of cancer in February
2009.
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper.